Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29834888 | 0.89 | HTR2A (0.65) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL5635157 | 0.89 | HTR2A (0.65) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL27598427 | 0.88 | HTR2A (0.63) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL1094688 | 0.86 | GPR84 (0.74) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL7004405 | 0.85 | HTR2A (0.73) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL9889542 | 0.83 | HTR2A (0.71) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL11603000 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL7391194 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL18328036 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2KDM4E | |
| SCHEMBL11359977 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772183-A | Indolylethyl fluoroboric acid derivatives, and preparation method and application thereof | 复旦大学 | 2023-03-10 | — | — | CN | disclosed |
| US-11420963-B2 | Rebamipide prodrugs, preparation method and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2022-08-23 | — | — | US | disclosed |
| US-20220162219-A1 | Chiral Bisamino-Ether Compounds, And Method of Preparation and Use Thereof | UNIV JINAN (CN) | 2022-05-26 | — | — | US | disclosed |
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | QUANTUM GENOMICS (FR) | 2021-12-07 | — | — | US | disclosed |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-10-07 | — | — | US | disclosed |
| CN-113166182-A | Aminopeptidase A inhibitor and pharmaceutical composition comprising the same | 量子基因公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| WO-2020007017-A1 | CHIRAL BISAMINO-ETHER COMPOUNDS, AND METHOD OF PREPARATION AND USE THEREOF | JINAN UNIVERSITY (CN) | 2020-01-09 | — | — | WO | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-4255432-A | ANTIHYPERTENSIVE AGENTS, ANTIHISTAMINES, BRONCHODILATOR AGENTS, ANTIVASOSPASTIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1981-03-10 | — | — | US | disclosed |
| US-4242347-A | Hypotensive indolylalkylpiperidyl guanidines and isoureas | CIBA-GEIGY CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| US-4147786-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-4073911-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-14 | — | — | US | disclosed |
| US-4066780-A | Pyranoindole derivatives as antiulcer agents | AYERST MCKENNA AND HARRISON LTD. (CA) | 1978-01-03 | — | — | US | disclosed |
| US-4066779-A | ANTIDEPRESSANT, ANTIULCER | AYERST, MCKENNA AND HARRISON LTD. (CA) | 1978-01-03 | — | — | US | disclosed |
| US-4041169-A | TREATING AND PREVENTING ULCERS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-08-09 | — | — | US | disclosed |
| US-4036842-A | FRIEDEL CRAFTS CATALYST | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-4021451-A | P-(3,4-DIHYDRO-1-METHYL-1H-(1)BENZOTHIENO(2,3-C)PYRAN-1-YL)PHENYL) -ACETIC ACID | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-03 | — | — | US | disclosed |
| US-4003913-A | ANTIDEPRESSANTS, ANTIULCER AGENTS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | ANPEP, DNPEP, ENPEP | HTR2A 3749/4885GPR84 1339/4885KEAP1 1303/4885 |
| US-20220162219-A1 | Chiral Bisamino-Ether Compounds, And Method of Preparation and Use Thereof | FHIT, BCAT1, BCAT2 | HTR2A 2377/4885GPR84 1112/4885KEAP1 1061/4885 |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ANPEP, DNPEP, ENPEP | HTR2A 3749/4885GPR84 1339/4885KEAP1 1303/4885 |
| US-11420963-B2 | Rebamipide prodrugs, preparation method and use thereof | SI, CYP2A7, MLN | HTR2A 3639/4885GPR84 1955/4885KEAP1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.